09/21/23 8:55 AMNasdaq : IMMX clinical trialfda approvallow floatU.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) AmyloidosisFDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified clinical testing Waiver of the Prescription Drug User Fee (currently at almost $3 million for a new drug) The Amyloidosis market was $3.6 billionRHEA-AIneutral
09/19/23 9:10 AMNasdaq : IMMX low floatImmix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing SiteImmixRHEA-AIneutral
09/07/23 8:41 AMNasdaq : IMMX conferenceslow floatNexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company ConferenceImmix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that Nexcella NXC-201 clinical data will beRHEA-AInegative
09/01/23 8:39 AMNasdaq : IMMX managementlow floatImmix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory BoardDr. Lentzsch joins the Nexcella Scientific Advisory Board with decades of experience treating patients with AL Amyloidosis and multiple myeloma and serving as a principal investigator on clinical trials for novel agents. Dr. Lentzsch is an internationally recognized expert in multiple myeloma andRHEA-AIneutral
08/23/23 8:37 AMNasdaq : IMMX clinical trialfda approvallow floatU.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple MyelomaFDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified clinical testing Waiver of the Prescription Drug User Fee (currently at almost $3 million for a new drug) The $13.9 billion Multiple Myeloma market in 2017 isRHEA-AIneutral
08/18/23 9:20 AMNasdaq : IMMX managementlow floatImmix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory BoardDr. Landau joins the Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Memorial Sloan Kettering Cancer Center Dr. Landau is a recognized thought leader in CAR-T cell therapy, bone marrow and solid organ transplantation and novel treatment approachesRHEA-AIneutral
08/16/23 9:05 AMNasdaq : IMMX clinical triallow floatImmix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece)Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that additional NXC-201 clinical data for relapsed/refractory ALRHEA-AInegative
07/25/23 8:42 AMNasdaq : IMMX clinical triallow floatImmix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual MeetingNexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), todayRHEA-AIneutral
07/17/23 9:37 AMNasdaq : IMMX clinical triallow floatImmix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical TrialTumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV relapsed/refractory metastatic colorectal cancer and received 8 median lines of therapy prior to IMX-110 + tislelizumabRHEA-AIneutral
07/10/23 9:47 AMNasdaq : IMMX low floatImmix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing SiteNexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced the completion of its initialRHEA-AInegative